Tag: Beta cells

  • Campus & Community

    Douglas Melton wins Ogawa-Yamanaka Stem Cell Prize

    Douglas Melton, co-director of Harvard Stem Cell Institute and the Xander University Professor in Harvard’s Department of Stem Cell and Regenerative Biology, has been awarded the 2016 Ogawa-Yamanaka Stem Cell Prize from the Gladstone Institutes.

  • Health

    First area cell transplantation center

    An expansive effort by several Harvard-affiliated units and hospitals has created the first cell transplantation center in the Boston area.

  • Health

    Potential diabetes treatment advances

    Researchers at MIT’s David H. Koch Institute for Integrative Cancer Research, in collaboration with scientists at the Harvard Stem Cell Institute and several other institutions, have developed an implantable device that in mice shielded insulin-producing beta cells from immune system attack for six months — a substantial proportion of life span.

  • Health

    Reprogramming cells, long term

    Harvard Stem Cell Institute researchers have demonstrated that adult cells, reprogrammed into another cell type in a living animal, can remain functional over a long period. The work is an important advance in the effort to develop cell-based therapies for tissue repair, and specifically in the effort to develop improved treatment for diabetes.

  • Health

    Giant leap against diabetes

    Harvard stem cell researchers announced a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a disease that affects an estimated 3 million Americans.

  • Health

    Potential diabetes breakthrough

    Researchers at the Harvard Stem Cell Institute have discovered a hormone that holds promise for a dramatically more effective treatment of type 2 diabetes, a metabolic illness afflicting an estimated 26 million Americans.

  • Health

    New hope against diabetes

    Results from a phase 1 drug trial by Harvard Medical School and Massachusetts General Hospital researchers showed that a decades-old tuberculosis drug knocked out the autoimmune cells that attack diabetic patients’ insulin-producing cells, followed by indications that pancreatic function was improving, albeit transiently.